



PTO/SB/088 (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/237,981
Filing Date	01/25/99
First Named Inventor	Thomas Quertermous
Art Unit	1644
Examiner Name	Patrick J. Nolan
Attorney Docket Number	213-0094US

Sheet	1	of	1
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PN		MILLIGAN, JOHN F., Current Concepts in Antisense Drug Design, Journal of Medicinal Chemistry, July 9, 1993, Pgs. 1923-1937, Vol. 36, No. 14, Gilead Sciences, Foster City, CA.	
PN		KRAMER, RANDALL H., Human Microvascular Endothelial Cells Use B1 and B3 Integrin Receptor Complexes to Attach to Laminin, The Journal of Cell Biology, September 1990, Pgs. 1233-1243, Vol. 111, The Rockefeller University Press.	
PN		BIANCHI, DIANA W., Detection of Fetal Cells With 47,XY,+21 Karyotype in Maternal Peripheral Blood, Human Genetics 90, June 16, 1992, Pgs. 368-370.	
		<del>International Search Report in related PCT application PCT/US96/09456, Quertermous et al.</del>	
PN		International Preliminary Examination Report in related PCT application PCT/US96/09456, Quertermous et al.	

Examiner Signature	<i>Pat J. Nolan</i>	Date Considered	8/10/04
--------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.